Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ally Bridge Starts Hedge Fund for Listed China Healthcare Companies

publication date: Jul 22, 2015
Ally Bridge Group, a Hong Kong-US investment firm, has opened a new fund that invests in listed China life science companies, including those on both the mainland and the Hong Kong exchanges. The fund, called the Ally Bridge LB Healthcare Fund, began operations on July 15, according to a Bloomberg report. It is described as a hedge fund, implying the fund intends to sell short overvalued companies while buying shares in attractively priced entities. Frank Yu, the founder and CEO of Ally Bridge, did not disclose how much money was raised for the fund. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital